Recursion Pharmaceuticals

US · RXRX #2649 by market cap Listed 2021

4.27 -0.36 -7.78%

Live - 5344 symbols - heartbeat 432s ago · 2026-10-08 08:29

Pre-market 4.21 -1.41%

After-hours 4.27 0.00%

Overnight 4.26 -0.23%

Market cap: 2.29B
P/E (TTM): -4.27
P/B: 2.50
EPS: -1.44
Div yield: 0.00%
52W pos: 34%

Reader sentiment Are you bullish or bearish on RXRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Distributing

The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
Total institutional ownership fell 5.1 percentage points.

Institutional ownership

Held by institutions: 67.63% -5.14pp
Institutions: 388 -1
As of: 2026/Q3 vs. prior period

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Mutual Fund52.35%

VC/PE Fund4.59%

Public Company4.44%

Individual/Insider2.98%

Hedge Fund2.91%

Sovereign Wealth Fund1.27%

Private Company1.12%

Family Office/Trust0.48%

Government Pension Fund0.34%

Other29.50%

Top holders as of 2026-06-30

BlackRock 9.38% · 50.30M sh

ARK Investment Management LLC 7.71% · 41.34M sh

State Street Global Advisors 6.47% · 34.71M sh

Vanguard Portfolio Management, LLC 5.81% · 31.13M sh

Vanguard Capital Management, LLC 4.89% · 26.24M sh

Baillie Gifford 4.38% · 23.49M sh

Geode Capital Management, LLC 2.58% · 13.82M sh

SoftBank Group Corp. 2.54% · 13.64M sh

DCVC 2.54% · 13.62M sh

UBS Asset Management 1.81% · 9.71M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 11 buys · 39 sells

Name	Role	Stake
Blake Borgeson	Co-Founder	1.13%
Christopher Gibson	Chief Executive Officer	1.00%
Dean Li	Co-Founder & Independent Director	0.60%
David Hallett	Chief Scientific Officer	0.08%
Ben Taylor	CFO & President of Recursion UK	0.06%
Najat Khan	Chief R&D Officer, Chief Commercial Officer & Director	0.03%
Zavain Dar	Independent Director	0.03%
Franziska Michor	Director	0.02%
Robert Hershberg	Independent Director	0.01%
Elaine Sun	Director	0.00%

Insider transactions most recent Form 4 filings

Date	Name	Role	Type	Shares	Price
2026-09-30	Dean Li	Co-Founder & Independent Director	Other Acquisition	+3,378	--
2026-09-30	Zavain Dar	Independent Director	Other Acquisition	+4,607	--
2026-09-14	Ben Taylor	CFO & President of Recursion UK	Sale to Issuer	-5,396	$3.41
2026-09-07	Najat Khan	Chief R&D Officer, Chief Commercial Officer & Director	Automatic Disposition	-22,408	$3.52
2026-08-31	Blake Borgeson	Co-Founder	Automatic Disposition	-30,000	$3.34
2026-08-20	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-77,290	$3.39
2026-08-19	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-75,000	$3.40
2026-08-18	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-100,000	$3.28
2026-08-17	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-26,806	$3.00
2026-08-16	Ben Taylor	CFO & President of Recursion UK	Sale to Issuer	-25,018	$3.16
2026-08-16	David Hallett	Chief Scientific Officer	Sale to Issuer	-26,657	$3.16
2026-08-16	Najat Khan	Chief R&D Officer, Chief Commercial Officer & Director	Sale to Issuer	-80,498	$3.16
2026-08-12	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-100,000	$3.31
2026-08-11	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-50,000	$3.37
2026-08-09	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-100,000	$3.27
2026-08-06	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-100,000	$3.25
2026-08-03	Blake Borgeson	Co-Founder	Automatic Disposition	-30,000	$3.25
2026-08-03	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-75,000	$3.27
2026-07-29	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-75,000	$3.00
2026-07-28	Christopher Gibson	Chief Executive Officer	Intent to Sell (Form 144)	-50,000	$3.03

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 08:29:38 · For reference only, not investment advice and not tailored to your situation.